Symbol: 
Dynamic Watchlist

Trading Activities Reports
OTCBB News
OTCBB News
OTC Equity Short Interest
SEC 605 Report
Investor Info.
Issuer Info.
Vendor Info.
OTCBB Rules
About OTCBB

 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
Business Summary: Med Gen, Inc. manufactures and markets healthcare products, primarily to the market for alternative therapies. Its flagship product is SNORenz, a throat spray, which reduces or eliminates the sounds ordinarily associated with snoring.
 
Address
  7280 W Palmetto Park Rd Ste 306
  Boca Raton , FL 33433-3401
  Phone: 561-750-1100
  Fax: 561-750-6239
  Website: http://www.medgen.com
Auditor
  Stark Winter Schenkein & Co.
Transfer Agent
  Continental Stock Transfer & Trust Co.
Employees:  8
ShareHolders:  2114
Founded:  1996
Domicile:  Nevada
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
Med Gen, Inc. manufactures and markets healthcare products, primarily to the market for alternative therapies. Its flagship product is SNORenz, a throat spray, which reduces or eliminates the sounds ordinarily associated with snoring. The company also provides other products, including Good Nights Sleep, a liquid throat spray formulation for sleep aide; PAINenz, a roll-on topical pain relief product for reducing the pain common to arthritis sufferers, normal aches, and pains due to exercise and other muscle stress, simple backache pain, and muscle sprains; and Fab U Lust a roll-on dispenser to dispense the ingredients for a female clitoral stimulant. In addition, Med Gen offers the UNDIET SYSTEM, a weight loss program; and markets CigarHolder, a plastic clip and holder capable of holding two cigars. The company sells its products through DRTV television and print advertising campaigns, as well as company owned and operated Web sites direct to the consumer, and through various distribution agreements. It also markets its products under various private labels for other distributors in the United States and internationally. Med Gen was founded in 1996 and is headquartered in Boca Raton, Florida.
History:  INCORPORATED in Nevada Oct. 22, 1996.
 
 
Capital Expenditures, thousand. US Dollars
  Year  Amount
  2007  16
  2006  19
  2005  5
 
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version

Management
OfficersPosition
 Paul B. KravitzChairman, Secretary, Chief Executive Officer & Investor Relations Contact
 Paul S. MitchellPresident, Treasurer & Chief Operating Officer
 Jack  ChienChief Financial Officer & Chief Accounting Officer

Directors
 Paul B. Kravitz
 Paul S. Mitchell
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
 
Capitalization as of 09/30/2007:
 
 Authorized SharesOutstanding Shares
Common $0.001 par12,495,000,0001,271,098,028
Preferred $0.001 par5,000,000None
 
LONG TERM DEBT: None.
 
Common $0.001 par
 
PRIVATE PLACEMENT: In January 2003, the company commenced a private placement of Common stock and warrants in units. The company offered a minimum of 1,250,000 and a maximum of 1,785,714 units at $2.80 per unit. Each unit consisted of one Common share and one warrant to purchase one Common share for a period of four years from the date of issuance.
 
Stockholders:  09/30/2007, 2114.
Transfer Agent:  Continental Stock Transfer & Trust Co.   New York , NY
 
OTC Bulletin Board( Primary): MDIN
 
ExchangeYearHighLow
OTC Bulletin Board20081.01000.0000
OTC Bulletin Board20070.01000.0100
OTC Bulletin Board20060.05700.0040
OTC Bulletin Board20050.89000.0160
OTC Bulletin Board20041.43000.0110
OTC Bulletin Board20032.20000.9000
OTC Bulletin Board20020.45000.0700
OTC Bulletin Board20011.37000.1300
OTC Bulletin Board20000.81200.0500
Over The Counter19991.06250.2813
 
DIVIDENDS: Common $0.001 par: No cash. Common reverse split 1-for-80, Feb. 3, 2003. Common was split 4-for-1, ex-Nov. 18, 2003.
 
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
Annual Report
 
Income Statement
  20072006
Revenue:
Net product sales148,190270,801
Consulting revenue1,616,970---
Total Revenue1,765,160270,801
Product sales166,505298,160
Consulting fees425,363---
Gross profit (loss)1,173,292(27,359)
Selling, general and administrative expenses3,824,4952,982,931
(Loss) from operations(2,651,203)(3,010,290)
Derivative instrument expense12,256,4524,974,603
Gain on the settlement of debt---(782,848)
Interest income(28,612)(15,829)
Interest expense586,734720,521
Net (loss)(15,465,777)(7,906,737)
Net (loss) per share - basic and diluted($0.03)($0.10)
Weighted average shares564,404,64778,935,487
 
Balance Sheet
  2007
ASSETS
Current Assets
Cash and cash equivalents1,250,009
Accounts receivable, net8,309
Inventory121,900
Other current assets6,138
Total Current Assets1,386,356
Property and Equipment, net30,191
Deferred financing fees110,103
Deposits and other assets45,089
TOTAL ASSETS1,571,739
LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses65,896
Accrued registrations penalties1,823,381
Accrued interest396,262
Derivative financial instruments13,821,497
Convertible debentures5,678,159
Accrued litigation judgment306,676
Total Current Liabilities22,091,871
Stockholders' (deficit)
Common Stock, $0.001 par1,271,098
Paid in capital28,001,047
Accumulated (deficit)(49,792,277)
Total stockholders' (deficit)(20,520,132)
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)1,571,739
Common Shares1,271,098,028
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
Interim Report   
 
Data Not Available
 
 
 
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
Pro Forma Report   
 
Data Not Available
 
 
 
 
  S & P Disclaimer
 

Med Gen, Inc.
Symbol:  MDIN


Click here for a printable version
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2008   1230,000
  2008   2490,000
  2008   3240,000
  2007   1180,000
  2007   2500,000
  2007   3740,000
  2007   4800,000
  2007   Full Year 1,770,000
  2006   1100,000
  2006   250,000
  2006   330,000
  2006   Full Year 270,000
  2005   1280,000
  2005   2200,000
  2005   3180,000
  2005   Full Year 800,000
  2004   1270,000
  2004   2240,000
  2004   3230,000
  2004   Full Year 1,040,000
  2003   1550,000
  2003   2590,000
  2003   3400,000
  2003   Full Year 2,310,000
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2008   1(19,830,000)
  2008   210,960,000
  2008   3(687,480,000)
  2007   1(1,150,000)
  2007   2(1,530,000)
  2007   3(2,990,000)
  2007   4(2,400,000)
  2007   Full Year (15,470,000)
  2006   1(780,000)
  2006   2(8,930,000)
  2006   3(960,000)
  2006   Full Year (7,906,700)
  2005   1(260,000)
  2005   2(550,000)
  2005   3(580,000)
  2005   Full Year (12,214,900)
  2004   1(460,000)
  2004   2(300,000)
  2004   3(1,290,000)
  2004   Full Year (9,171,300)
  2003   160,000
  2003   2(3,030,000)
  2003   3(180,000)
  2003   Full Year (592,800)
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2008   1(2.00)
  2008   2.66
  2008   3(19.86)
  2007   1Nil
  2007   2Nil
  2007   3(2.00)
  2007   4(2.00)
  2007   Full Year (5.48)
  2006   1(24.00)
  2006   2(66.00)
  2006   3(2.00)
  2006   Full Year (20.00)
  2005   1(40.00)
  2005   2(80.00)
  2005   3(80.00)
  2005   Full Year (#######)
  2004   1(480.00)
  2004   2(200.00)
  2004   3(320.00)
  2004   Full Year (#######)
  2003   1370.00
  2003   2(80.00)
  2003   3(730.00)
  2003   Full Year (#######)
 
  S & P Disclaimer